-
Kanamycin Sulfate: Designing Better Microbial Assays
2026-09-08
Kanamycin Sulfate is a water-soluble antibiotic whose value extends beyond routine microbial selection. This article presents an assay-design framework connecting bacterial protein synthesis inhibition with toxin-focused anti-infection research, using the CAPE study in Clostridioides difficile as a model for stronger experimental interpretation.
-
Cytochalasin B: Actin Workflow for S2 Entry Studies
2026-09-07
Cytochalasin B (NSC 107658) provides a reversible way to test whether actin dynamics support endocytosis, intracellular trafficking, or cell movement. This workflow translates findings from Spiroplasma eriocheiris-infected Drosophila S2 cells into practical assay design, controls, and troubleshooting guidance.
-
CFDA-SE: From Cell Division to Surfaceome Insight
2026-09-05
A translational framework for combining CFDA-SE-based proliferation histories with nanobody-TurboID surfaceome mapping to distinguish cell-state changes from cell-surface mechanism.
-
SD 169: Practical p38 MAPK Research Workflows
2026-09-05
SD 169 (indole-5-carboxamide) gives researchers a practical way to interrogate p38α/β signaling across inflammation, type 1 diabetes research, and nerve repair models. This workflow-focused guide combines ATP-competition controls, phosphatase-aware assays, and troubleshooting strategies for more interpretable results.
-
BAPTA and the Logic of Causal Calcium Biology
2026-09-04
BAPTA is more than a calcium chelator: it is a causal perturbation tool for testing whether intracellular Ca2+ sits upstream of apoptosis and pathway activation. Evidence from nanoplastic–cadmium intestinal toxicity illustrates how BAPTA can strengthen mechanistic inference while guiding translational assay design, exposure interpretation, and reproducibility.
-
Sodium Butyrate, HDAC3/c-Myc, and Liver Fibrosis
2026-09-04
This FASEB Journal study identifies an HDAC3/c-Myc-driven glycolytic program in activated hepatic stellate cells and shows that gut-derived sodium butyrate suppresses this pathway in cellular and CCl4-induced mouse models. The work connects a microbiota-derived metabolite with epigenetic and metabolic control of fibrosis, while also outlining assays that can be used to validate target engagement and pathway activity.
-
(S)-(+)-Ibuprofen: From COX Biology to Translation
2026-09-03
A translational framework for using (S)-(+)-Ibuprofen as a stereochemically defined COX inhibitor, linking prostaglandin biology, assay design, exposure strategy, synthesis advances, and environmental stewardship.
-
DFO: Reliable Fluorescent Workflows
2026-09-03
This evidence-led guide explains where DFO (9H-1,8-Diazafluoren-9-one), SKU C6997, is scientifically appropriate and where it should not be substituted for a cell-viability reagent. It connects forensic fluorescence practice with practical controls, formulation data, and vendor-selection criteria for reproducible laboratory workflows.
-
AMPK–JAK2/STAT3 in Obesity-Related Asthma
2026-09-02
A 2025 study identifies reduced AMPK activity and M1 macrophage polarization as linked features of obesity-related asthma, with evidence that AMPK activation attenuates airway inflammation through the JAK2/STAT3 pathway. Its combined animal, cell-based, histological, transcriptional, and protein analyses provide a mechanistic framework for studying immunometabolic regulation in this asthma phenotype.
-
4μ8C Workflows for IRE1α and ER Stress Studies
2026-09-02
4μ8C provides a practical way to separate IRE1α RNase signaling from broader ER stress effects in hypoxia and cancer research. This guide translates its formulation limits, pathway selectivity, and assay behavior into reproducible workflows while clarifying how recent TBK1–itaconic acid findings can inform, but not replace, IRE1-focused experiments.
-
Epalrestat: From Polyol Pathway to Nrf2 Assays
2026-09-01
Epalrestat is an aldose reductase inhibitor with a distinctive research profile spanning polyol pathway inhibition and KEAP1/Nrf2-linked neuroprotection. This guide translates recent Parkinson’s disease model findings into practical, mechanism-resolved assay decisions.
-
Exemestane: Steroidal Aromatase Inhibition
2026-08-31
Exemestane is a steroidal aromatase inhibitor that irreversibly inactivates cytochrome P450 aromatase and suppresses androgen-to-estrogen conversion. Its reported biochemical activity, chemical identity, solvent compatibility, and storage guidance support controlled enzyme, cell-based, and breast cancer research workflows.
-
Clozapine N-oxide (CNO) for Chemogenetic Workflows
2026-08-31
Clozapine N-oxide (CNO) enables reversible, circuit-level control of engineered GPCRs, making it useful for linking neuronal activity modulation to behavior and physiology. This practical guide translates a VTA–parabrachial nucleus anesthesia study into formulation, dosing, controls, and troubleshooting decisions for modern DREADD experiments.
-
Wnt-C59: A Secretion-Centric Wnt Assay Strategy
2026-08-30
Wnt-C59 is a potent PORCN inhibitor for separating Wnt ligand production, trafficking, and pathway activation. This article connects its use in cancer biology with a mechanistic assay framework inspired by lithium-engineered exosomal Wnt10a research.
-
ECL Western Blotting Substrate: Workflow Guide
2026-08-29
ECL Western Blotting Substrate (SKU K2187) is a luminol-based horseradish peroxidase detection reagent for nonradioactive Western blot assays using X-ray film or CCD imaging. It is intended for HRP chemiluminescence workflows and should not be used as a substitute for fluorescent or radioisotopic detection methods.